Management of Hyperlipidemia and Related Conditions
Introduction to Treatment Approaches
- The American Diabetes Association recommends initiating fenofibrate therapy for moderate hypertriglyceridemia, starting at 54-160 mg daily, to reduce cardiovascular risk 1
- The American College of Cardiology suggests that after initiating fenofibrate, consider adding moderate-intensity statin therapy to address elevated LDL cholesterol 1
Laboratory Analysis and Diagnosis
- Patients with moderate hypertriglyceridemia, significantly elevated LDL cholesterol, and elevated total cholesterol may be diagnosed with mixed dyslipidemia 2
Treatment of Dyslipidemia
- Fenofibrate can reduce triglyceride levels by 30-50% and increase HDL cholesterol, addressing two components of dyslipidemia 2, 3
- The combination of fenofibrate and statin therapy should be monitored carefully for muscle symptoms and liver function abnormalities 1
Management of Impaired Fasting Glucose
- The American Diabetes Association recommends initiating metformin therapy for impaired fasting glucose, targeting HbA1c of <7% to improve glucose control and triglyceride levels 2
Lifestyle Modifications
- Dietary changes focusing on restriction of added sugars to <6% of total daily calories, limitation of total fat to 30-35% of total daily calories, and reduction of saturated fat intake are recommended 2, 3, 4
- Target 5-10% weight loss, which can reduce triglycerides by approximately 20% 2
- Recommend at least 150 minutes/week of moderate-intensity or 75 minutes/week of vigorous aerobic activity 2, 3
Monitoring and Follow-up
- Reassess fasting lipid panel in 6-12 weeks after implementing therapy 2
- Monitor liver function and creatine kinase levels when using fenofibrate or combination therapy 1, 2